The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This morning, which is understandable with a Mcap of £7.5mm
GLA SR
Wildbunch: I think "independent tester" may mean the Contract Research Organisation (CRO), Simbec-Orion, which will be carrying out the Phase 3 Lupuzor trial.
Wildbunch: I think "independent tester" may mean the Contract Research Organisation (CRO), Simbec-Orion, which will be carrying out the Phase 3 Lupuzor trial.
Older-what is this independent tester doing? sure you are right but heard of it before.
Thanks.
....when our independent tester reports back but must be due soon. Seems like nearly 6 months since they started work, And if the news is equivocal, may not decide to RNS. So all we can do is wait. Frustrating!
New uncle. Definitely another string to our bow. Dallo is right though we could do with some news. Have a great weekend.
Hi Yorkshire,
Does at least explain the retrace seen since the shares recovered previously on the back of the RNS about Incathera growth orders.
Commenting on Incanthera's announcement, Dr Tim Franklin, COO of ImmuPharma said: "As a major shareholder in Incanthera, we are delighted with this further progress and in particular Incanthera's revenue momentum and move into profitability. This highlights the strong financial asset we have in Incanthera and the enormous opportunities within the company's revolutionary skincare range and its partnership with Marionnaud."
Lanstead has sold c 12m shares since last notification late last year and only notified today when it's shareholding dropped below 13% even though Lanstead should have notified when it's holding went below 15%.
It gave me the false impression that it had not sold shares in recent months...silly me!
We really need some positive newsflow very soon or the share price will continue to drift.
ATB
As expected, to keep the SP down to lower their monthly payments. The only reason it was unclear, was because the holdings on the website hadn't been updated since January, which it still hasn't.
New uncle. Exactly as you pointed out.
Lansted still selling shares apparently.
Thanks
" before September when Immupharma has to come up with c£700,000 to exercise the 7.3 million warrants at 9.5p. "
They may well extend the date , maybe Tim is already lobbing for that
Fully agree. Those who follow will be brimming with FOMO. Many like me will be happy to help them at the right price by selling a proportion as I can take a generous profit and still be in the game - all wonderful IF it goes to plan!!!
Hi Yorkshire,
FYI, Technical Analysis on small caps like this isn't all that reliable. What I have noticed is that there have been consistent sellers since IMM peaked at 2.5p from its 1p lows and they have been selling every single day and no evidence that has really stopped yet fwiw. That said daily volumes have been smaller over last month or so it wouldn't take much buying to see the price rise quickly, all guesswork in the end though.
GL
PB = Price Break Out
POI = Point Of Interest
What is poi in a trading chart?
Poi, also known as Point of Interest, is a popular technical analysis tool used in the forex market. It is a concept that involves identifying specific price levels where the market is likely to experience a significant change in direction.
Wigwammer
Agreed.
However should the Incanthera revenues start to accelerate over the coming months as forecast by Uncle Tim , it is conceivable we could see a sharp increase in the Incanthera share price and accordingly in the value of Immupharma's shareholding and warrants in Incanthera.
The OTC market where Incanthera is listed is very illiquid and has very few daily trades so good news from Incanthera could lead to a sharp spike in the SP hopefully before September when Immupharma has to come up with c£700,000 to exercise the 7.3 million warrants at 9.5p.
ATB
In English?
A poss pb poi area on weekly
https://invst.ly/14ntyj
True Dallo - the treatment of the warrants will affect the value of the incanthera assets, but also the number of immupharma shares we use - diluted or undiluted - will affect the value of the stake on a per share basis. For the sake of identifying that the stake is currently not worth anything like 1.25p a share, the 0.2p approximation was perfectly sufficient… ATB
Immupharma owns 10.8% of Incanthera plus has warrants to subscribe for c7.3m shares at 9.5p exercisable by September of this year...Incanthera share price is c13p at present.
To resolve the Incathera debate once & for all:
IMM owns c. 10%, so at Incanthera's current market cap of around £10.5m, IMM's stake is worth £1.05m.
IMM's current market cap is c. £8.65m and its share price is trading at around 2.1p.
So theoretically, Incanthera is worth 1.05/8.65 x 2.1p to IMM. Which equates to 0.255p per share.
In other words, Wigwammer was far closer to being right on this than oldbutnowisa.
Still, even 0.255p a share's worth having when you're currently only trading at 2.1p.
Well you can disagree all you want. But there is simply no way our stake/warrants/options in incanthera are worth 1.25p per immupharma share, or over £5m. This is simple maths. ATB
Disagree Wigwammer. We own 10% of Incanthera plus options as far as I can see, but what matters here is an update on the geeks who are poring over P140 etc.
Not sure that’s correct, oldbutnowisa. The Imm stake in incanthera is currently worth around £1m. Current immupharma market cap is around £9m at 2.2p and that’s before dilution re warrants, options, and so on. So the stake is worth around 0.2p per immupharma share (a bit more if we include the incanthera options we own). ATB